BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 9098191)

  • 1. Two-step immunoscintigraphy for non-small-cell lung cancer staging using a bispecific anti-CEA/anti-indium-DTPA antibody and an indium-111-labeled DTPA dimer.
    Vuillez JP; Moro D; Brichon PY; Rouvier E; Brambilla E; Barbet J; Peltier P; Meyer P; Sarrazin R; Brambilla C
    J Nucl Med; 1997 Apr; 38(4):507-11. PubMed ID: 9098191
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radioimmunodetection of medullary thyroid carcinoma using indium-111 bivalent hapten and anti-CEA x anti-DTPA-indium bispecific antibody.
    Barbet J; Peltier P; Bardet S; Vuillez JP; Bachelot I; Denet S; Olivier P; Leccia F; Corcuff B; Huglo D; Proye C; Rouvier E; Meyer P; Chatal JF
    J Nucl Med; 1998 Jul; 39(7):1172-8. PubMed ID: 9669389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biodistribution and dosimetric study in medullary thyroid cancer xenograft using bispecific antibody and iodine-125-labeled bivalent hapten.
    Hosono M; Hosono MN; Kraeber-Bodéré F; Devys A; Thédrez P; Fiche M; Gautherot E; Barbet J; Chatal JF
    J Nucl Med; 1998 Sep; 39(9):1608-13. PubMed ID: 9744353
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunoscintigraphy using 111in-labelled F(ab')2 fragments of anti-carcinoembryonic antigen (CEA) monoclonal antibody for staging of non-small cell lung carcinoma.
    Vuillez JP; Moro D; Brambilla E; Brichon PY; Ferretti G; Saccavini JC; Brambilla C
    Eur J Cancer; 1994; 30A(8):1089-92. PubMed ID: 7654435
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pretargeted radioimmunoscintigraphy in patients with primary colorectal cancer using a bispecific anticarcinoembryonic antigen CEA X anti-di-diethylenetriaminepentaacetic acid F(ab')2 antibody.
    Aarts F; Boerman OC; Sharkey RM; Hendriks T; Chang CH; McBride WJ; Bleichrodt RP; Oyen WJ; Goldenberg DM
    Cancer; 2010 Feb; 116(4 Suppl):1111-7. PubMed ID: 20127959
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bispecific antibody and bivalent hapten radioimmunotherapy in CEA-producing medullary thyroid cancer xenograft.
    Kraeber-Bodéré F; Faibre-Chauvet A; Saï-Maurel C; Gautherot E; Fiche M; Campion L; Le Boterff J; Barbet J; Chatal JF; Thédrez P
    J Nucl Med; 1999 Jan; 40(1):198-204. PubMed ID: 9935077
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bispecific monoclonal antibody-mediated targeting of an indium-111-labeled DTPA dimer to primary colorectal tumors: pharmacokinetics, biodistribution, scintigraphy and immune response.
    Le Doussal JM; Chetanneau A; Gruaz-Guyon A; Martin M; Gautherot E; Lehur PA; Chatal JF; Delaage M; Barbet J
    J Nucl Med; 1993 Oct; 34(10):1662-71. PubMed ID: 8410279
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radioimmunodetection of medullary thyroid cancer using a bispecific anti-CEA/anti-indium-DTPA antibody and an indium-111-labeled DTPA dimer.
    Peltier P; Curtet C; Chatal JF; Le Doussal JM; Daniel G; Aillet G; Gruaz-Guyon A; Barbet J; Delaage M
    J Nucl Med; 1993 Aug; 34(8):1267-73. PubMed ID: 8326383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radioimmunotherapy of small cell lung carcinoma with the two-step method using a bispecific anti-carcinoembryonic antigen/anti-diethylenetriaminepentaacetic acid (DTPA) antibody and iodine-131 Di-DTPA hapten: results of a phase I/II trial.
    Vuillez JP; Kraeber-Bodéré F; Moro D; Bardiès M; Douillard JY; Gautherot E; Rouvier E; Barbet J; Garban F; Moreau P; Chatal JF
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3259s-3267s. PubMed ID: 10541373
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bispecific antibody and iodine-131-labeled bivalent hapten dosimetry in patients with medullary thyroid or small-cell lung cancer.
    Bardiès M; Bardet S; Faivre-Chauvet A; Peltier P; Douillard JY; Mahé M; Fiche M; Lisbona A; Giacalone F; Meyer P; Gautherot E; Rouvier E; Barbet J; Chatal JF
    J Nucl Med; 1996 Nov; 37(11):1853-9. PubMed ID: 8917192
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radioimmunoimaging of non-small cell lung cancer with 111In- and 99mTc-labeled monoclonal anti-CEA-antibodies.
    Kairemo KJ; Aronen HJ; Liewendahl K; Paavonen T; Heikkonen JJ; Virkkunen P; Mäki-Hokkonen H; Karonen SL; Brownell AL; Mäntylä MJ
    Acta Oncol; 1993; 32(7-8):771-8. PubMed ID: 8305225
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunohistology of carcinoembryonic antigen (CEA)-expressing tumors grafted in nude mice after radioimmunotherapy with 131I-labeled bivalent hapten and anti-CEA x antihapten bispecific antibody.
    Gautherot E; Kraeber-Bodéré F; Daniel L; Fiche M; Rouvier E; Saï-Maurel C; Thedrez P; Chatal JF; Barbet J
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3177s-3182s. PubMed ID: 10541361
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Delivery of therapeutic doses of radioiodine using bispecific antibody-targeted bivalent haptens.
    Gautherot E; Le Doussal JM; Bouhou J; Manetti C; Martin M; Rouvier E; Barbet J
    J Nucl Med; 1998 Nov; 39(11):1937-43. PubMed ID: 9829586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pretargetted imaging of colorectal cancer recurrences using an 111In-labelled bivalent hapten and a bispecific antibody conjugate.
    Chetanneau A; Barbet J; Peltier P; Le Doussal JM; Gruaz-Guyon A; Bernard AM; Resche I; Rouvier E; Bourguet P; Delaage M
    Nucl Med Commun; 1994 Dec; 15(12):972-80. PubMed ID: 7715897
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bispecific-antibody-mediated targeting of radiolabeled bivalent haptens: theoretical, experimental and clinical results.
    Le Doussal JM; Barbet J; Delaage M
    Int J Cancer Suppl; 1992; 7():58-62. PubMed ID: 1428406
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-CEA immunoscintigraphy and computed tomographic scanning in the preoperative evaluation of mediastinal lymph nodes in lung cancer.
    Buccheri G; Biggi A; Ferrigno D; Quaranta M; Leone A; Vassallo G; Pugno F
    Thorax; 1996 Apr; 51(4):359-63. PubMed ID: 8733485
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting of indium 111-labeled bivalent hapten to human melanoma mediated by bispecific monoclonal antibody conjugates: imaging of tumors hosted in nude mice.
    Le Doussal JM; Gruaz-Guyon A; Martin M; Gautherot E; Delaage M; Barbet J
    Cancer Res; 1990 Jun; 50(11):3445-52. PubMed ID: 2334941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pre-clinical and clinical studies of two new bifunctional chelating agents for immunoscintigraphy with 111In-anti-CEA monoclonal antibody.
    Faivre-Chauvet A; Mease RC; Chetanneau A; Bardiès M; Sai-Maurel C; Meinken GE; Srivastava SC; Chatal JF; Gestin JF
    Nucl Med Commun; 1996 Sep; 17(9):781-9. PubMed ID: 8895905
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Two-step targeting and dosimetry for small cell lung cancer xenograft with anti-NCAM/antihistamine bispecific antibody and radioiodinated bivalent hapten.
    Hosono M; Hosono MN; Kraeber-Bodéré F; Devys A; Thédrez P; Faivre-Chauvet A; Gautherot E; Barbet J; Chatal JF
    J Nucl Med; 1999 Jul; 40(7):1216-21. PubMed ID: 10405144
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bispecific antibody pretargeting PET (immunoPET) with an 124I-labeled hapten-peptide.
    McBride WJ; Zanzonico P; Sharkey RM; Norén C; Karacay H; Rossi EA; Losman MJ; Brard PY; Chang CH; Larson SM; Goldenberg DM
    J Nucl Med; 2006 Oct; 47(10):1678-88. PubMed ID: 17015905
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.